title: Matrix metalloproteinase- 9 polymorphisms in the diagnosis of prostate cancer. A preliminary experience.
abstract: Polymorphisms Q279R, P574R and -1562 C/T of matrix metalloproteinase-9 (MMP-9) gene have been linked with the risk of cancer and with tumoral aggressiveness in various types of cancer. So far there are no studies in the literature analysing the link between polymorphisms Q279R, P574R and -1562 C/T of MMP-9 and prostate cancer.
  
  
  OBJECTIVE
  To establish the presence of the MMP-9's gene polymorphisms (Q279R, P574R and -1562 C/T)in relation to results of prostate biopsy, PSA values and Gleason score.
  
  
  METHODS
  Hospital cohort of 100 patients with suspected prostate cancer, subjected to prostate biopsy, in whom the MMP-9 polymorphisms (Q279R, P574R and -1562 C/T) were analysed using the PCR-RLFP technique.
  
  
  RESULTS
  No statistically significant differences were found in the presence of the Q279R, P574R and -1562 C/T polymorphisms in terms of prostate biopsy results (p = 0.264, p = 0.406, p = 0.860, respectively), or Gleason score (p = 0.373, p = 0.367, p = 0.476). Comparing the genotypes of the Q279R, P574R and -1562 C/T polymorphisms resulting from prostate biopsy, using subgroups according to PSA values, no statistically significant differences were found either (p = 0.332 y p = 0.393, respectively ). However, statistically significant differences were found when comparing the genotypes of the -1562 C/T polymorphism of the MMP-9 in patients showing positive biopsy for malignant tumour in comparison to a negative biopsy for a malignant tumour in the subgroup of patients with PSA 10 ng/ml (p=0.049). The joint analysis of the three MMP-9 polymorphisms, using logistical regression study did not reveal any statistically significant differences as far as the risk of developing prostate cancer is concerned based on the presence of the Q279R, P574R and -1562 C/T polymorphisms.
  
  
  CONCLUSIONS
  The Q279R, P574R and -1562 C/T polymorphisms are not linked with the aggressiveness in prostate cancer, neither they are linked to the risk of suffering prostate cancer.
authors.affiliation: Urology Department, Hospital de Cabueñes, Gijon, Asturias, Spain.
authors.forename: Rodrigo
authors.initials: R
authors.lastname: Gil Ugarteburu
authors.forename: Manuel
authors.initials: M
authors.lastname: Rivas del Fresno
authors.forename: Iván
authors.initials: I
authors.lastname: González Rodríguez
authors.forename: Patricia
authors.initials: P
authors.lastname: González Arriaga
authors.forename: Felicitas
authors.initials: F
authors.lastname: López Cima
authors.forename: Ana
authors.initials: A
authors.lastname: Fernández Samoano
authors.forename: Isabel
authors.initials: I
authors.lastname: Fernández García
authors.forename: Priscila
authors.initials: P
authors.lastname: Benito García
authors.forename: Valentín
authors.initials: V
authors.lastname: Muruamendiaraz Fernández
authors.forename: Adonina
authors.initials: A
authors.lastname: Tardón
mesh_terms: D000230:Adenocarcinoma / Q000175:diagnosis* / Q000235:genetics*; D000368:Aged; D000369:Aged, 80 and over; D006801:Humans; D008297:Male; D020780:Matrix Metalloproteinase 9 / Q000235:genetics*; D008875:Middle Aged; D011110:Polymorphism, Genetic; D011471:Prostatic Neoplasms / Q000175:diagnosis* / Q000235:genetics*
chemical_list: D020780:Matrix Metalloproteinase 9